ClinicalTrials.gg
CompletedNCT07102459Updated Apr 29, 2026

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

A Phase 2 interventional study of Experimental: LTG-001 High Dose and Experimental: LTG-001 Low Dose in Acute Pain and Postoperative Pain Control, sponsored by Latigo Biotherapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Latigo Biotherapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
39th of 320
343 · median 84
Started
2025
with 14 others
Phase 2
54 of 351
6 open now
Registered
334th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 39th largest by enrollment of the 320 interventional ones that give a count, is one of 15 that started in 2025, is one of 54 in phase 2, and was the 334th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001.

The main questions it aims to answer are:

Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain?

Participants will:

Take LTG-001 bid after the surgical abdominoplasty. Remain at the clinic for approximately 48 hours during study dosing and return after two weeks for a safety check up. Report the pain relief during the 48 hours to record changes in the post-operative pain.

03

Conditions studied

  • Acute Pain
  • Postoperative Pain Control

Browse trials for

Keywords

  • Acute Pain
  • Abdominoplasty
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged 18 to 65 years
  • Scheduled to undergo an elective "partial" abdominoplasty under general anesthesia
  • Has a body 18.0 to 35 kg/m2
  • Has signed and will comply with the requirements and restrictions of the study
  • Meet lifestyle, medication, or other study restrictions
  • Subject must agree to study required use of
  • Post-surgical (abdominoplasty) pain must meet the study threshold

Exclusion criteria

Exclusion Criteria:

  • Inability to take oral medications
  • Prior abdominoplasty or a prior intra-abdominal and/or pelvic surgery (including hysterectomy and Cesarean section) that resulted in any complications
  • History of impaired hepatic function or heart disease.
  • Abnormal liver laboratories or other lab abnormality indicative of serious medical condition
  • Sensory abnormality that would confound post-surgery pain assessments
  • Chronic use of NSAIDs, benzodiazepines, opioid use within the last year, use of medications that prolong , or other dietary and medication restrictions
  • A subject with sleep apnea and/or on a home continuous positive airway pressure machine.
  • Positive drug screen.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    LTG-001 High Dose

    High Dose LTG-001

    Drug: Experimental: LTG-001 High Dose

  • Experimental
    LTG-001 Low Dose

    Drug: Experimental: LTG-001 Low Dose

  • Active comparator
    HB/APAP

    Drug: Active Comparator: HB/APAP

  • Placebo comparator
    Placebo

    Drug: Placebo Comparator

Interventions

06

What researchers measure

Primary outcomes

  1. SPIDr0-48

    Time-weighted SPIDr0-48 after the first dose of study drug.

    Time frame: 48 hours

Secondary outcomes

  1. Total Opioid Rescue

    Total opioid rescue medication consumption from 0 48 hours, using MMEs

    Time frame: 48 hours

  2. No Opioid requirement

    Proportion of participants requiring no opioid rescue medication over 48 hours

    Time frame: 48 hours

  3. 2-Point NPRS Reduction

    Time to ≥2-point reduction in NPRS from baseline

    Time frame: 48 hours

  4. 1-Point NPRS Reduction

    Time to ≥1-point reduction in NPRS from baseline

    Time frame: 48 Hours

  5. Nausea and Vomiting

    Incidence of nausea or vomiting

    Time frame: 48 hours

  6. PID at 60 minutes

    Time-specific PID at 60 minutes

    Time frame: 1 hour

  7. SPID r0-24

    Time-weighted SPIDr0-24 after the first dose of study drug

    Time frame: 24 hours

  8. Patient Global Assessment

    Proportion of participants with favorable PGA of study drug at end of treatment

    Time frame: 48 Hours

07

Study locations

5 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • CenExel ACMR
    Atlanta, Georgia 30331, United States
  • HD Research LLC
    Houston, Texas 77043, United States
  • Endeavor Clinical Research
    San Antonio, Texas 78240, United States
  • JBR Clinical Research (CenExel)
    Salt Lake City, Utah 84107, United States
08

References and documents

Publications

  • Singla N, Katz NP, Vaughn B, Rogier T, Bertoch T, Minkowitz H, Loflin M. Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain. N Engl J Med. 2026 Jul 30;395(5):454-464. doi: 10.1056/NEJMoa2602910. PubMed 42526026 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jan 2026, 5 months.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Jul 24, 2025
Primary completionActual
Jan 7, 2026
CompletionActual
Jan 7, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07102459
Lead sponsor
Latigo Biotherapeutics
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Jul 24, 2025
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update
Apr 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTG-001

Start the discussion